Seelos to Test Potential Parkinson’s Treatment Targeting Alpha-synuclein Clumps

Seelos to Test Potential Parkinson’s Treatment Targeting Alpha-synuclein Clumps
Seelos Therapeutics has acquired an exclusive license to further develop a treatment approach called SLS-007 for Parkinson’s disease which is intended to lessen the aggregation of alpha-synuclein protein. The therapeutic strategy was developed by scientists at University of California, Los Angeles, and includes a family of peptide blockers that target the build-up of alpha-synuclein — a major constituent of Lewy bodies found in ... read more
Source: Parkinson’s News TodayPublished on 2019-03-12By Jose Marques Lopes, PhD